Allergan (NYSE:AGN)‘s stock had its “buy” rating reissued by equities research analysts at Wells Fargo & Co in a research report issued on Wednesday.
AGN has been the topic of a number of other reports. Guggenheim started coverage on shares of Allergan in a research report on Monday, October 8th. They set a “buy” rating on the stock. Argus reissued a “hold” rating on shares of Allergan in a research report on Thursday, July 5th. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Credit Suisse Group set a $213.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Friday, July 13th. Finally, Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $193.00 price target on the stock in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $210.18.
AGN opened at $164.46 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.85 and a current ratio of 1.21. Allergan has a fifty-two week low of $142.81 and a fifty-two week high of $197.00. The stock has a market cap of $54.54 billion, a P/E ratio of 9.30, a PEG ratio of 1.25 and a beta of 1.19.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.21. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same period last year, the firm earned $4.15 earnings per share. The firm’s revenue was down 3.0% on a year-over-year basis. Equities research analysts predict that Allergan will post 16.4 EPS for the current fiscal year.
In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of Allergan stock in a transaction dated Thursday, September 6th. The stock was purchased at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph H. Boccuzi bought 900 shares of Allergan stock in a transaction dated Thursday, August 30th. The stock was acquired at an average price of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Company insiders own 0.36% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of AGN. Thompson Siegel & Walmsley LLC increased its stake in shares of Allergan by 3,032.4% in the second quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock worth $146,337,000 after purchasing an additional 849,719 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Allergan by 27,066.5% in the second quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock worth $131,347,000 after purchasing an additional 784,928 shares in the last quarter. Mainstay Capital Management LLC ADV increased its stake in shares of Allergan by 13,097.2% in the second quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock worth $4,288,000 after purchasing an additional 669,924 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Allergan by 16.3% in the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after purchasing an additional 668,343 shares in the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of Allergan by 85.4% in the second quarter. Orbimed Advisors LLC now owns 1,286,205 shares of the company’s stock worth $214,436,000 after purchasing an additional 592,600 shares in the last quarter. Hedge funds and other institutional investors own 77.58% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Story: Earnings Reports
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.